NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01437787,Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis,https://clinicaltrials.gov/study/NCT01437787,JAKARTA,COMPLETED,"Primary Objective:

* To evaluate the efficacy of daily oral doses of 400 mg or 500 mg of SAR302503 (Investigational Medicinal Product, IMP) compared to placebo in the reduction of spleen volume as determined by magnetic resonance imaging (MRI) (or computed tomography scan in patients with contraindications for MRI).

Secondary Objectives:

* To evaluate the effect on Myelofibrosis (MF)-associated symptoms (key MF symptoms) as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary.
* To evaluate the Overall Survival of patients treated with either 400 mg/day or 500 mg/day of IMP as compared to placebo.
* To evaluate the Progression Free Survival of patients treated with either 400 mg/day or 500 mg/day of IMP as compared to placebo.
* To evaluate the durability of splenic response.
* To evaluate the safety of IMP.",NO,Hematopoietic Neoplasm,DRUG: SAR302503|DRUG: Placebo,"Response Rate (RR), defined as the proportion of patients who have a ≥35% reduction in volume of spleen size at the end of Cycle 6, and confirmed 4 weeks thereafter, 6 months","Symptom Response Rate (SRR): Proportion of patients with ≥50% reduction from baseline to the end of Cycle 6 in the total symptom score., This assessment will be conducted through the modified MFSAF diary, which will be completed during the week prior to Day 1 of each treatment cycle up to Cycle 6, and during the week prior to the end of Cycle 6., 6 months|OS (overall survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo., approximately 5 years|PFS (progression free survival) of either 400 mg/day or 500 mg/day of IMP as compared to placebo., approximately 5 years|Proportion of patients who have ≥25% reduction in volume of spleen size at end of Cycle 6, and confirmed 4 weeks thereafter., 6 months|Duration of spleen response, measured by MRI (or CT scan in patients with contraindications for MRI., 2 years|Clinical and laboratory events graded by the NCI CTCAE v4.03., approximately 5 years",,Bristol-Myers Squibb,,ALL,"ADULT, OLDER_ADULT",PHASE3,289,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",EFC12153|2011-001897-25|U1111-1121-7170,2011-12,2014-06,2014-06,2011-09-21,,2025-03-25,"Investigational Site Number 840014, Scottsdale, Arizona, 85259-5499, United States|Investigational Site Number 840001, La Jolla, California, 92093, United States|Investigational Site Number 840012, La Jolla, California, 92093, United States|Investigational Site Number 840006, Los Angeles, California, 90033, United States|Investigational Site Number 840013, Baton Rouge, Louisiana, 70808, United States|Investigational Site Number 840008, Rochester, Minnesota, 55905, United States|Investigational Site Number 840009, Newark, New Jersey, 07112, United States|Investigational Site Number 840002, Canton, Ohio, 44718, United States|Investigational Site Number 840004, Houston, Texas, 77030, United States|Investigational Site Number 036001, Box Hill, 3128, Australia|Investigational Site Number 036005, Herston, 4029, Australia|Investigational Site Number 036003, Randwick, 2031, Australia|Investigational Site Number 036004, Tweed Heads, 2485, Australia|Investigational Site Number 036002, Wodonga, 3690, Australia|Investigational Site Number 040001, Wien, 1090, Austria|Investigational Site Number 056003, Antwerpen, 2060, Belgium|Investigational Site Number 056001, Leuven, 3000, Belgium|Investigational Site Number 076002, Jau, 17210-120, Brazil|Investigational Site Number 076004, Porto Alegre, 90110-270, Brazil|Investigational Site Number 076001, Rio De Janeiro, 20230-130, Brazil|Investigational Site Number 124001, Montreal, H1T 2M4, Canada|Investigational Site Number 124003, Montreal, H2W 1S6, Canada|Investigational Site Number 124002, Saint John, E2L 4L2, Canada|Investigational Site Number 250006, Marseille, 13273, France|Investigational Site Number 250005, Nantes Cedex 01, 44093, France|Investigational Site Number 250004, Nimes, 30029, France|Investigational Site Number 250002, Pierre Benite Cedex, 69495, France|Investigational Site Number 250007, Poitiers, 86000, France|Investigational Site Number 250003, Toulouse, 31000, France|Investigational Site Number 250001, Villejuif Cedex, 94805, France|Investigational Site Number 276006, Aachen, 52074, Germany|Investigational Site Number 276007, Bonn, 53127, Germany|Investigational Site Number 276008, Dresden, 01307, Germany|Investigational Site Number 276001, Mannheim, 68167, Germany|Investigational Site Number 348002, Budapest, 1097, Hungary|Investigational Site Number 348001, Debrecen, 4032, Hungary|Investigational Site Number 348007, Györ, 9023, Hungary|Investigational Site Number 348006, Kecskemét, 6000, Hungary|Investigational Site Number 348003, Miskolc, 3529, Hungary|Investigational Site Number 372002, Dublin, DUBLIN 8, Ireland|Investigational Site Number 372001, Galway, Ireland|Investigational Site Number 376003, Haifa, 31048, Israel|Investigational Site Number 376002, Tel Hashomer, 52621, Israel|Investigational Site Number 380002, Bergamo, 24127, Italy|Investigational Site Number 380007, Bologna, 40138, Italy|Investigational Site Number 380004, Firenze, 50134, Italy|Investigational Site Number 380001, Pavia, 27100, Italy|Investigational Site Number 380006, Pavia, 27100, Italy|Investigational Site Number 380003, Varese, 21100, Italy|Investigational Site Number 410002, Bundang-Gu, 463-707, Korea, Republic of|Investigational Site Number 410004, Seoul, 110-744, Korea, Republic of|Investigational Site Number 410003, Seoul, 120-752, Korea, Republic of|Investigational Site Number 410001, Seoul, 135-710, Korea, Republic of|Investigational Site Number 410005, Seoul, 137-701, Korea, Republic of|Investigational Site Number 410006, Seoul, 138-878, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 440001, Kaunas, LT-50009, Lithuania|Investigational Site Number 440002, Klaipeda, LT-92288, Lithuania|Investigational Site Number 484001, Queretaro, 76000, Mexico|Investigational Site Number 616005, Brzozow, 36-200, Poland|Investigational Site Number 616002, Gdansk, 80-952, Poland|Investigational Site Number 616006, Lodz, 93-510, Poland|Investigational Site Number 616010, Warszawa, 02-106, Poland|Investigational Site Number 616003, Wroclaw, 50-367, Poland|Investigational Site Number 620005, Coimbra, 3000-075, Portugal|Investigational Site Number 620004, Lisboa, 1169-050, Portugal|Investigational Site Number 620001, Lisboa, 1649-035, Portugal|Investigational Site Number 620003, Porto, 4200-072, Portugal|Investigational Site Number 642003, Brasov, Romania|Investigational Site Number 642004, Bucharest, 022328, Romania|Investigational Site Number 642002, Bucuresti, 030171, Romania|Investigational Site Number 642006, Bucuresti, Romania|Investigational Site Number 642001, Timisoara, Romania|Investigational Site Number 643009, Moscow, 125167, Russian Federation|Investigational Site Number 643001, Moscow, 125284, Russian Federation|Investigational Site Number 643010, Nizhny Novgorod, 603126, Russian Federation|Investigational Site Number 643008, Petrozavodsk, 185019, Russian Federation|Investigational Site Number 643004, St-Petersburg, 197341, Russian Federation|Investigational Site Number 643005, St.-Petersburg, 191024, Russian Federation|Investigational Site Number 643007, Volgograd, 400138, Russian Federation|Investigational Site Number 702002, Singapore, 119228, Singapore|Investigational Site Number 702001, Singapore, 169608, Singapore|Investigational Site Number 710003, Johannesburg, 2013, South Africa|Investigational Site Number 710002, Parktown, 2193, South Africa|Investigational Site Number 724001, Barcelona, 08036, Spain|Investigational Site Number 724002, Madrid, 28046, Spain|Investigational Site Number 752001, Stockholm, 14186, Sweden|Investigational Site Number 752002, Uddevalla, 451 80, Sweden|Investigational Site Number 158002, Changhua, 500, Taiwan|Investigational Site Number 158003, Kaohsiung, 833, Taiwan|Investigational Site Number 158001, Taipei, 112, Taiwan|Investigational Site Number 826006, Belfast, BT9 7AB, United Kingdom|Investigational Site Number 826003, Birmingham, B9 5SS, United Kingdom|Investigational Site Number 826002, Glasgow, G12 0YN, United Kingdom|Investigational Site Number 826004, Leeds, LS9 7TF, United Kingdom|Investigational Site Number 826001, London, SE1 9RT, United Kingdom|Investigational Site Number 826005, London, W12 0HS, United Kingdom|Investigational Site Number 826007, Manchester, M20 4BX, United Kingdom|Investigational Site Number 826008, Newcastle Upon Tyne, NE7 7DN, United Kingdom|Investigational Site Number 826009, Oxford, OX3 7LJ, United Kingdom|Investigational Site Number 826010, Southampton, SO16 6YD, United Kingdom",
